Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Intralymphatic Ragweed Mix Injections for Allergic Conjunctivitis and Rhinitis
NCT03038971Phase 1Terminated
- Sponsor
- Woodmont Pharmaceuticals, Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of short ragweed + tall ragweed in allergic conjunctivitis (AC) and allergic rhinitis (AR) (3 arms), sponsored by Woodmont Pharmaceuticals, Inc. Primary endpoints: Adverse events (reported, elicited and observed) at 47 weeks, Local Injection Site Tolerability and Reactivity; pain at 47 weeks and 3 more. Started Mar 2017; status: terminated.
02
Drugs
short ragweed + tall ragweed
03
Conditions
allergic conjunctivitis (AC)allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03038971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038971.